Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano Purchases 3,250 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano purchased 3,250 shares of Precision BioSciences stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average price of $5.30 per share, for a total transaction of $17,225.00. Following the completion of the acquisition, the director now owns 11,057 shares of the company’s stock, valued at approximately $58,602.10. This trade represents a 41.63 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Precision BioSciences Stock Up 0.2 %

DTIL opened at $4.54 on Friday. Precision BioSciences, Inc. has a one year low of $3.61 and a one year high of $15.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a market capitalization of $34.83 million, a P/E ratio of 75.68 and a beta of 1.59. The business’s 50-day simple moving average is $5.12 and its 200-day simple moving average is $6.59.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($1.11). Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. Analysts anticipate that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on DTIL shares. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research report on Wednesday, March 19th.

Hedge Funds Weigh In On Precision BioSciences

A number of large investors have recently modified their holdings of the company. Squarepoint Ops LLC purchased a new stake in Precision BioSciences during the 4th quarter worth $179,000. Tang Capital Management LLC increased its position in Precision BioSciences by 8.0% in the 4th quarter. Tang Capital Management LLC now owns 673,332 shares of the company’s stock valued at $2,565,000 after acquiring an additional 50,000 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Precision BioSciences by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock worth $59,000 after purchasing an additional 2,805 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Precision BioSciences by 58.0% in the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock worth $586,000 after purchasing an additional 56,400 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Precision BioSciences in the 4th quarter valued at $146,000. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.